Arrivent Biopharma Inc

AVBP is in Stage 3 distribution with an active Lower Highs & Lower Lows pattern signaling supply dominance. Price is rejecting near the falling 9 and 20 EMAs, confirming bearish execution into the EMA resistance zone. Long-term uptrend remains intact above the rising 200DMA but is secondary to the current downtrend.

• ↑Moderate Buy consensus with $44.43 PT implies ~50% upside
• ↑Guggenheim and BTIG Buy ratings reinforce analyst confidence
• ↓Q2 reported $93M loss underscores ongoing cash burn